Ocata Therapeutics Inc fka OCAT

[Dragon Lady]

10-Q out first glance read: CASH LOW and a few other items of note.

http://ir.ocata.com/sec-filings/content/0001019687-15-001797/ocata_10q-033115.htm

PAGE 1: 35,667,442 shares O/S as of April 30, 2015

From the balance sheet, PAGE 3:
Cash is 3,532,602

Immediate accounts payable is 1,191,185

So at best, their current cash position is about $3,532,602 - $1,191,185 = $2,341,417 ( a little over $2 mil left, which they burn every month approx)

Thus they will be tapping Lincoln ASAP for more dilution funding IMO.

PAGE 4, statement of operations:

Their R&D + general/Admin expenses for the qtr: 7,065,433

So they are burning about 7,065,433 / 3 = $2.3 MILLION PER MONTH

Their qtr loss was $7,035,071 which means they're tracking to LOSE about $28 MILLION this yr which is up considerably.(considering the legal expense nonsense was paid off and not in this qtr expenses) They're burning money like it's going out of style.
(wow, and that's with no major trials being funded yet)

PAGE 19:

"We have no therapeutic products currently available for sale and do not expect to have any therapeutic products commercially available for sale for a period of years, if at all. These factors indicate that our ability to continue research and development activities is dependent upon the ability of management to obtain additional financing as required."

PAGE 20 (they spent more on R&D but NO TRIALS BEING FUNDED. Just says they're "preparing" for trials)

"R&D expenditures, excluding non-cash stock compensation expense, increased from $2,422,659 for the three months ended March 31, 2014 to $2,822,853 for the same period in 2015, for an increase of $400,194 or 16.5%. The increase in R&D expenditures was primarily due to an increase in employee costs of approximately $202,000, an increase in expenses related to travel and conferences of approximately $163,000, an increase in costs related to our scientific advisory board of approximately $83,000, and an increase in consulting expenses of approximately $38,000. These increases were partially offset by decreases in pre-clinical program expenditures of approximately $79,000 and lab supplies of approximately $40,000. These shifts in expenditures were driven primarily by our shift in focus from pre-clinical programs to our planned expansion of our clinical capabilities as we continue to prepare for the commencement of our Phase 2 clinical trial in AMD and Pivotal clinical trial in SMD."

NOTHING NEW that I can see? Just BURNING CASH TO PAY THEIR OVERHEAD SALARIES and biz as usual- NO key "trials" underway, NO myth of a JV or whatever, nothing else mentions. JUST DILUTION and business "as usual" IMO. Not a "new" thing in the entire 10-Q on my 5 minute, first-pass quick read version

Will double check it again later- but I see NOTHING "new" or of major "news" in it- dilution and spend. That's about it.